ERBB2 and gastric adenocarcinoma: The dose-escalation trial NCT02795988 for the evaluation of HER-Vaxx included an adult patient who was diagnosed with T4N3M1 stage IV Her-2/neu+++ adenocarcinoma of the stomach with four target lesions (2x liver and 2x lymph) and five non-target lesions and who received, in addition to cisplatin-5FU chemotherapy, a total of seven vaccinations (50 μg dose).